<SEC-DOCUMENT>0001123292-24-000396.txt : 20241219
<SEC-HEADER>0001123292-24-000396.hdr.sgml : 20241219
<ACCEPTANCE-DATETIME>20241219161545
ACCESSION NUMBER:		0001123292-24-000396
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20241219

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Xilio Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840233
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851623397
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92962
		FILM NUMBER:		241563452

	BUSINESS ADDRESS:	
		STREET 1:		828 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-833-1027

	MAIL ADDRESS:	
		STREET 1:		828 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001193125-24-088525</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0000882095</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>1</amendmentNo>
<securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/18/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001840233</issuerCik>
<issuerName>Xilio Therapeutics, Inc.</issuerName>
<issuerCusip>98422T100</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>828 Winter Street, Suite 300</com:street1>
<com:city>Waltham</com:city>
<com:stateOrCountry>MA</com:stateOrCountry>
<com:zipCode>02451</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>GILEAD SCIENCES INC</reportingPersonName>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>9105451</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>9105451</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>9105451</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>19.9</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>Items 5, 7, 9: Consists of (A) 6,860,223 shares of common stock, par value $0.0001 per share (the "Common Stock"), of Xilio Therapeutics, Inc. (the "Issuer") issued to the Reporting Person on March 28, 2024, (B) 485,250 shares of Common Stock issued to the Reporting Person on April 3, 2024, and (C) 1,759,978 shares of Common Stock issued to the Reporting Person on December 18, 2024.&#13;
&#13;
Item 11: Based on 43,996,060 shares of Common Stock issued and outstanding as of December 10, 2024, according to information provided by the Issuer, plus 1,759,978 shares of Common Stock issued to the Reporting Person on December 18, 2024.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Xilio Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>828 Winter Street, Suite 300, Waltham, Massachusetts, 02451</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>Gilead Sciences, Inc.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>333 Lakeside Drive &#13;
Foster City, California 94404</principalBusinessOfficeOrResidenceAddress>
<citizenship>Delaware</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>9,105,451</amountBeneficiallyOwned>
<classPercent>19.9</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>9,105,451</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>9,105,451</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>GILEAD SCIENCES INC</reportingPersonName>
<signatureDetails>
<signature>/s/ Andrew D. Dickinson</signature>
<title>Executive Vice President and Chief Financial Officer</title>
<date>12/19/2024</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
